source
- Genmab shares jump as petosemtamab plus Keytruda halves death risk in head-neck cancer trialGenmab reported that a late-stage study of its experimental antibody petosemtamab combined with Keytruda cut the risk of death by about 50 percent compared with Keytruda alone in patients with PD‑L…
- Eli Lilly beats Q3 revenue forecasts, lifts full-year outlookEli Lilly reported third-quarter revenue of $24.4 billion, roughly $2 billion above analysts' expectations. The outperformance underscores the company's strong position, driven in part by its GLP-…